Targeting the neural cell adhesion molecule in cancer.
NCAM is a tumour associated antigen expressed on small cell lung cancer, neuroblastoma, rhabdomyosarkoma, brain tumours, multiple myelomas and acute myeloid leukaemia. Constant and strong expression of NCAM is a prerequisite for the development of antibody-based immunotherapies. From the spectrum of existing anti-NCAM compounds, radioimmunoconjugates and immunotoxins represent the clinically most advanced and successful strategies. Here we provide an overview of the evolving field of anti-NCAM immunotherapy for cancer and discuss its indications and limitations.
Jensen
Markus
M
Department of Paediatric Oncology and Haematology, University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany. jensen@uni-koeln.de
Berthold
Frank
F
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D019006:Neural Cell Adhesion Molecules / Q000276:immunology*
D000911:Antibodies, Monoclonal; D019006:Neural Cell Adhesion Molecules